Summary & Overview
Urethral Stricture: Inpatient Reimbursement Overview
DRG 697 encompasses inpatient encounters for treatment of urethral stricture, including dilation, urethrotomy, and reconstructive approaches; it defines the clinical scope for grouping services related to relief of urethral obstruction. This grouping matters for inpatient reimbursement because it determines the bundled payment hospitals receive from the Centers for Medicare & Medicaid Services under the Medicare Severity Diagnosis-Related Group system.
DRG 697 Overview
DRG 697 covers inpatient admissions for urethral stricture procedures and related management, typically involving urethral dilation, urethrotomy, reconstruction, or catheter-related interventions. This Diagnosis-Related Group captures cases where the primary focus is correction or palliation of urethral narrowing that impairs urinary flow. For Medicare payment, DRG 697 groups clinically similar hospital stays to determine bundled reimbursement for facility services during the inpatient encounter. Accurate coding and documentation of procedures and any Complication or Comorbidity or Major Complication or Comorbidity affect payment assignment within the Medicare Severity Diagnosis-Related Group structure.
Clinical Trials
- Studies evaluating novel minimally invasive urethral dilation and internal urethrotomy techniques: These trials compare short-term and long-term patency outcomes, complication rates, and time to re-intervention for different minimally invasive procedures in adult men with bulbar or penile urethral strictures. The patient population typically includes those with single short strictures or recurrent disease managed without open reconstruction, and results inform inpatient procedure selection, length of stay, and expected resource use relevant to hospital billing and payer authorization.
- Comparative effectiveness research on urethroplasty approaches and timing: Randomized or observational cohort studies contrast excisional primary anastomosis, graft (buccal mucosa) substitution urethroplasty, and staged repairs across patients with varying stricture length, location, and etiology (traumatic, iatrogenic, or inflammatory). These studies address recurrence rates, functional outcomes (voiding and sexual function), perioperative morbidity, and readmission rates, providing evidence that influences DRG-level cost profiles, decisions about inpatient versus outpatient pathways, and long-term reimbursement considerations.
- Post-discharge outcomes and health services research focusing on recurrence, re-intervention, and quality of life: Longitudinal registry-based or prospective cohort studies follow patients after index admission for strictures to measure rates of repeat procedures, urinary tract infections, catheter dependence, patient-reported urinary function, and healthcare utilization over months to years. This research is relevant to payers and providers by quantifying downstream costs, identifying predictors of high resource use, and informing care coordination, follow-up protocols, and value-based payment models for patients assigned to this DRG.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.